Core Viewpoint - The document outlines the internal reporting system for significant information at Jiangxi Fuxiang Pharmaceutical Co., Ltd, aiming to ensure timely, accurate, and complete disclosure of information to protect investors' rights [1][2]. Group 1: Internal Reporting System - The internal reporting system is designed to manage significant information that may impact the company's stock and derivatives trading prices [1][2]. - The system applies to the company, wholly-owned subsidiaries, controlling subsidiaries, and affiliated companies [1]. Group 2: Reporting Obligations - Internal information reporters include company directors, senior management, department heads, shareholders holding more than 5% of shares, and other relevant personnel [1][2]. - The board of directors is responsible for managing significant information and its disclosure [2]. Group 3: Definition of Significant Information - Significant information includes matters submitted for board or audit committee review, major transactions exceeding 10% of audited annual revenue or net profit, and significant litigation or arbitration matters exceeding 10 million RMB [3][4]. - Other categories of significant information include major changes in operations, environmental issues, and risks related to major shareholders or actual controllers [5][6]. Group 4: Reporting Procedures - Departments must report potential significant information to the board secretary immediately upon awareness [8][9]. - The reporting process includes timely updates on the progress of significant matters and any changes that may affect stock prices [9][10]. Group 5: Management and Responsibility - The company implements a real-time reporting system for significant information, ensuring that all relevant parties report accurately and promptly [18][19]. - The securities affairs department and board secretary are responsible for preparing and disclosing periodic reports, including annual and quarterly reports [19][20].

第一条 为完善公司治理结构，规范公司董事、高级管理人员提名程序， 为公司选拔合格的董事、高级管理人员，根据《中华人民共和国公司法》《上市 公司治理准则》《公司章程》及其他有关规定，公司特设立董事会提名委员会，并 制定本工作规则。 江西富祥药业股份有限公司 （2025年6月） 第一章 总则 第四条 提名委员会成员由三名董事组成，其中独立董事2名。 第三条 提名委员会负责研究董事、高级管理人员的选择标准和程序并 提出建议；广泛搜寻合格的董事和高级管理人员的人选；对董事候选人和高级 管理人员候选人选进行审查并提出建议。 第二条 提名委员会为董事会下设的专门委员会，对董事会负责。 第五条 提名委员会成员由董事长、二分之一以上独立董事或者全体董 事的三分之一提名，并由董事会选举产生。 第六条 提名委员会设主任委员（召集人）一名，由独立董事委员担任， 负责主持委员会工作；主任委员在委员内选举，并报请董事会批准产生。 第七条 提名委员会委员的任期与其在董事会任期一致，委员任期届满， 连选可以连任。期间如有委员不再担任公司董事职务，自动失去委员资格， 并由委员会根据上述第四至第五条规定补足委员人数。 第三章 职责权限 第八条 ...

江西富祥药业股份有限公司 二零二五年六月 第一章 总则 第一条 为规范江西富祥药业股份有限公司（以下简称"公司"）募集资金管理和 使用，提高募集资金使用效益，防范募集资金使用风险，确保资金使用安全，建立分 工明确、权责明晰的投资管理体系，充分体现可靠、科学、高效的投资决策原则，保 障公司及股东的合法权益，根据《中华人民共和国公司法》 《中华人民共和国证券法》 《上市公司监管指引第2号—上市公司募集资金管理和使用的监管要求》《深圳证券 交易所上市公司自律监管指引第2号——创业板上市公司规范运作》《深圳证券交易 所创业板股票上市规则》及《江西富祥药业股份有限公司章程》（以下简称"《公司 章程》"）等相关法律、法规和规范性文件的规定，结合公司实际情况，制订本管理 办法。 第二条 公司应当建立并完善募集资金存储、使用、变更、监督和责任追究的制度， 明确募集资金使用的分级审批权限、决策程序、风险控制措施及信息披露要求，保证 募集资金项目的正常进行。 第三条 本制度所称募集资金是指公司通过公开发行证券(包括首次公开发行股票、 配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券、发行权证等) 以及非公开发行股票向 ...

Core Viewpoint - The document outlines the foreign exchange hedging policy of Jiangxi Fuxiang Pharmaceutical Co., Ltd., emphasizing risk management and compliance with relevant laws and regulations [3][4][5]. Summary by Sections General Provisions - The policy aims to standardize the foreign exchange hedging activities of the company and its subsidiaries to effectively prevent and control risks [3]. - Foreign exchange hedging activities are defined as transactions conducted with qualified financial institutions to mitigate exchange rate or interest rate risks [3]. Operational Regulations for Foreign Exchange Hedging - The company will not engage in hedging solely for profit; all activities must be based on normal business operations and aimed at risk avoidance [4]. - Transactions are restricted to approved financial institutions, and the company must establish its own hedging accounts [4][5]. - The company must have sufficient self-owned funds to match the margin for hedging activities and cannot use raised funds for these transactions [4]. Approval Authority for Foreign Exchange Hedging - All hedging activities require approval from the board of directors or shareholders, with specific thresholds for reporting to shareholders based on investment amounts [5][6]. - The chairman of the board or authorized personnel are responsible for the implementation and management of hedging activities [6]. Management and Internal Procedures - The finance department is responsible for the execution of hedging activities, including planning, funding, and daily management [7]. - The audit department oversees the actual operations of hedging activities, ensuring compliance and monitoring financial performance [7]. Confidentiality and Risk Reporting - All personnel involved in hedging must adhere to confidentiality protocols regarding the company's hedging strategies and financial information [8]. - In the event of significant risks or losses, the finance department must report to the board and propose countermeasures [8]. Information Disclosure - The company is required to disclose relevant information regarding its foreign exchange hedging activities in accordance with regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange [8]. Miscellaneous - The policy will take effect upon approval by the board and will be interpreted by the board of directors [9].

Core Points - Jiangxi Fushine Pharmaceutical Co., Ltd. aims to maximize shareholder value while providing safe and effective pharmaceutical products globally [3][4] - The company was established on August 29, 2012, and registered with a capital of RMB 538,648,934 [3][4] - The company operates as a public limited company and is governed by its articles of association, which are legally binding [2][3] Company Structure - The company is a permanent public limited company, with the chairman acting as the legal representative [2][3] - Shareholders are liable only to the extent of their subscribed shares, while the company is responsible for its debts with its total assets [2][3] - The articles of association provide a framework for the rights and obligations of shareholders, directors, and senior management [2][3] Business Objectives and Scope - The company's business objective is to maximize shareholder interests and innovate in the pharmaceutical sector [3][4] - The business scope includes the production and import/export of pharmaceuticals and hazardous chemicals, among other activities [3][4] Share Issuance and Management - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [4][5] - The total number of shares issued is 538,648,934, all of which are ordinary shares [4][5] - The company cannot provide financial assistance for others to acquire its shares, except under specific conditions [5][6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company governance [9][10] - Shareholders must comply with laws and the articles of association, and they cannot withdraw their capital except as legally permitted [14][15] - The articles outline the responsibilities of controlling shareholders and actual controllers to protect the interests of the company and other shareholders [14][15] Shareholder Meetings - The company holds annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [47][48] - Shareholder proposals must be submitted in advance, and the company must provide adequate notice of meetings [57][58] - The articles specify the voting procedures and requirements for decision-making during shareholder meetings [63][64]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开第四 届董事会第二十八次会议，审议通过了《关于修订 <公司章程> 及制定、修改部分管理 制度的议案》。根据《公司法》《上市公司章程指引》等有关法律法规的规定和要求， 并结合公司实际情况，公司决定修订《公司章程》及制定、修改部分管理制度，具体 内容如下： 一、修订《公司章程》情况 鉴于公司拟将回购账户中 11,355,900 股用途由"用于实施员工持股计划或股权激 励"变更为"用于注销并减少注册资本"。本次股份注销和减资完成后，公司总股本 减少 11,355,900 股，公司总股本将由 550,004,834 股变更为 538,648,934 股。注册资本 由人民币 550,004,834 元变更为人民币 538,648,934 元。同时，根据《公司法》《上市 公司章程指引》《上市公司信息披露管理办法》等有关法律法规及规范性文件的最新 修订和更新情况，公司修订《江西富祥药业股份有限公司章程》，其中公司拟调整三 会结构，将不再设置监事会 ...

Core Points - The document outlines the operational guidelines and management structure of Jiangxi Fuxiang Pharmaceutical Co., Ltd, emphasizing the need for institutionalization, standardization, and scientific management to ensure sound decision-making [2][3] Group 1: General Provisions - The company aims to adapt to modern corporate governance requirements and ensure the correctness and rationality of major business decisions [2] - The General Manager is responsible for daily operations under the Board of Directors' leadership and must execute board resolutions [2] Group 2: Appointment of General Manager - The General Manager and Board Secretary are nominated by the Chairman and appointed by the Board of Directors, while other senior management is nominated by the General Manager [3] - The General Manager's term is three years, with the possibility of reappointment [3] Group 3: Powers and Responsibilities of the General Manager - The General Manager has the authority to manage daily operations, implement annual plans, and propose internal management structures [5][6] - In emergencies, the General Manager can make temporary decisions outside their usual authority but must report to the Board afterward [5] Group 4: Responsibilities of the Deputy General Manager - The Deputy General Manager assists the General Manager and is responsible for their designated duties, reporting regularly to the General Manager [7] Group 5: Financial Responsibilities - The company appoints a Financial Officer responsible for managing financial activities and ensuring compliance with financial regulations [9] - The Financial Officer must report to the General Manager and participate in major financial decision-making [9] Group 6: Dismissal of the General Manager - The Board of Directors must dismiss the General Manager under specific circumstances, such as the end of the term or failure to meet appointment conditions [10][11] - The General Manager cannot resign without prior approval from the Board, especially in critical situations [11][12]

Core Viewpoint - The company has established a system to enhance the accountability of annual report information disclosure, aiming to improve the quality and transparency of financial reporting and ensure compliance with relevant laws and regulations [1][2][3]. Group 1: Accountability and Responsibility - The system applies to all personnel involved in the annual report disclosure process, including major shareholders, directors, senior management, and relevant staff, holding them accountable for significant economic losses or negative social impacts caused by non-compliance [1][2]. - The company emphasizes strict adherence to the "Enterprise Accounting Standards" and internal control systems to ensure that financial reports accurately reflect the company's financial status, operational results, and cash flows [2][3]. Group 2: Identification of Major Errors - Major errors in annual report disclosures include significant accounting errors in financial reports, substantial discrepancies in performance forecasts, and other significant omissions or errors in disclosures [2][3][4]. - Specific criteria for identifying major accounting errors include discrepancies exceeding 5% of total audited assets, net assets, revenues, or net profits, with absolute amounts exceeding 5 million [4][5]. Group 3: Correction and Audit Procedures - When significant errors are identified, the company must engage a qualified accounting firm to audit the corrected financial reports [5][6]. - The internal audit department is responsible for collecting relevant information, investigating causes, and proposing corrective measures, which must be reviewed by the board of directors [5][6]. Group 4: Consequences of Major Errors - The company will pursue accountability for individuals responsible for significant errors in annual report disclosures, including the chairman, general manager, and financial officers, who bear primary responsibility for the accuracy and completeness of financial reports [6][7]. - Penalties for responsible individuals may include internal criticism, warnings, demotions, or even termination of employment, depending on the severity of the error [7][8].

证券代码：300497 证券简称：富祥药业 公告编号：2025-043 江西富祥药业股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 1、会议名称：2025 年第二次临时股东大会。 2、会议召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会的召集、召开程序符合有关法律、 行政法规、部门规章、规范性文件和公司章程的规定。 本次股东大会的召开经公司第四届董事会第二十八次会议审议通过。 4、会议时间： （1）现场会议召开时间为：2025 年 7 月 14 日（星期一）下午 14:30 （2）网络投票时间：2025 年 7 月 14 日，其中，通过深圳证券交易所系统进行网 络投票的时间为 2025 年 7 月 14 日上午 9：15—9：25，9：30—11：30，下午 13：00 —15：00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 7 月 14 日 9：15-15：00 的任意时间。 5、会议召开方式：本次股东大会采取现场会议投票与网络投票相结合的方式。 公司将通过深圳证券 ...

一、监事会会议召开情况 江西富祥药业股份有限公司（以下简称"公司"）第四届监事会第十八次会议通 知于 2025 年 6 月 25 日以电子邮件等方式通知全体监事，并于 2025 年 6 月 27 日以现 场及通讯的方式举行。会议应出席监事 3 人，实际出席会议的监事 3 人。会议由监事 会主席杨海滨主持。会议召开和表决程序符合《中华人民共和国公司法》等法律、法 规及本公司章程的有关规定，合法有效。 证券代码：300497 证券简称：富祥药业 公告编号：2025-042 江西富祥药业股份有限公司 第四届监事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 1、审议通过《关于变更回购股份用途并注销的议案》 经审核，监事会认为：公司本次变更回购股份用途并注销的事项符合《上市公司 股份回购规则》和《深圳证券交易所上市公司自律监管指引第 9 号一一回购股份》等 法律、法规及规范性文件的有关规定，且审议程序合法合规，不会对公司的财务状况 和经营成果产生重大不利影响，也不存在损害公司及全体股东利益的情形。 表决结果：3 票同意，0 票反对，0 票弃权。 ...